GlassScriptPhysician profile
Peter Sidarous
NPI 1881072544
$1,881.97
in general payments reported to CMS, 2019-2025
27 companies · $574 in 2025
The $574 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $168 · 2021: $136 · 2022: $303 · 2023: $205 · 2024: $311 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $310.81 | 2022-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $227.14 | 2024-2025 | Gemtesa |
| Horizon Therapeutics Plc | $210.42 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $174.25 | 2022-2025 | Nuzyra, Xhance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.95 | 2020-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.57 | 2019-2023 | Jardiance |
| Amgen INC. | $93.46 | 2024-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $89.42 | 2020-2025 | Ebglyss, Mounjaro |
| Novo Nordisk INC | $74.20 | 2024-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $50.99 | 2019-2020 | |
| Dexcom, INC. | $39.75 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $39.19 | 2019-2024 | Farxiga |
| Glaxosmithkline, LLC. | $34.24 | 2022-2023 | Trelegy Ellipta |
| Exact Sciences Corporation | $31.53 | 2025 | Cologuard Collection Kit |
| Biodelivery Sciences International, INC. | $26.92 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $26.28 | 2025 | |
| Ardelyx, INC. | $25.03 | 2025 | Ibsrela |
| Amneal Pharmaceuticals LLC | $23.87 | 2023 | Lyvispah |
| Scynexis, INC. | $21.02 | 2022 | |
| Merck Sharp & Dohme LLC | $19.19 | 2023 | Belsomra, Steglatro |
| Kowa Pharmaceuticals America, INC. | $17.73 | 2025 | Zoryve |
| Seqirus USA INC | $14.69 | 2024 | Fluad, Flucelvax |
| Abbvie INC. | $14.46 | 2022 | |
| Zyla Life Sciences, INC. | $14.14 | 2019 | |
| Nevro Corp. | $14.01 | 2024 | Senza |
| Currax Pharmaceuticals LLC | $13.94 | 2025 | Contrave, Onzetra Xsail |
| Vertical Pharmaceuticals, LLC | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Sidarous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.